BRPI0509079A - molécula de ácido nucléico, vetor, célula hospedeira, partìculas tipo vìrus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal - Google Patents
molécula de ácido nucléico, vetor, célula hospedeira, partìculas tipo vìrus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animalInfo
- Publication number
- BRPI0509079A BRPI0509079A BRPI0509079-2A BRPI0509079A BRPI0509079A BR PI0509079 A BRPI0509079 A BR PI0509079A BR PI0509079 A BRPI0509079 A BR PI0509079A BR PI0509079 A BRPI0509079 A BR PI0509079A
- Authority
- BR
- Brazil
- Prior art keywords
- hpv
- pharmaceutical compositions
- virus
- vlps
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
MOLéCULA DE áCIDO NUCLéICO, VETOR, CéLULA HOSPEDEIRA, PART CULAS TIPO VìRUS, MéTODO PARA PRODUZIR VLPs, VACINA, COMPOSIçõES FARMACêUTICAS, E , MéTODOS PARA EVITAR INFECçãO POR HPV E PARA INDUZIR UMA RESPOSTA IMUNE EM UM ANIMAL São providas moléculas de DNA sintéticas, codificando a proteína L1 do HPV 52. especificamente, a presente inveção provê polinucleotídeos codificando a proteína L1 do HPV 52, em que ditos polinuleotídeos são otimizados por códons para expressão de alto nível em uma célula de levedura. Em formar de realização alternativas da invenção, a sequência de nucleotídeo da molécula sintética é alterada para para eliminar os sinais de terminação de transcrição, que são reconhecidos pela levedura. As moléculas sintéticos podem ser usadas para produzir partículas tipo vírus (VLPs) do HPV 52 e para vacinas e composições farmacêuticas compreendendo as VLPs do HPV 52. As vacinas da presente invenção fornecem imunoprofilaxia eficaz contra infecção por papilomavírus, através da neutralização de anticorpo e imunidade mediada por célula e podem também ser usadas para tratamento das existentes infecções por HPV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55592604P | 2004-03-24 | 2004-03-24 | |
| PCT/US2005/009199 WO2005097821A1 (en) | 2004-03-24 | 2005-03-18 | Optimized expression of hpv 52 l1 in yeast |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0509079A true BRPI0509079A (pt) | 2007-08-21 |
| BRPI0509079B1 BRPI0509079B1 (pt) | 2020-05-19 |
| BRPI0509079B8 BRPI0509079B8 (pt) | 2021-07-06 |
Family
ID=34964085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0509079A BRPI0509079B8 (pt) | 2004-03-24 | 2005-03-18 | molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7700103B2 (pt) |
| EP (1) | EP1730175B1 (pt) |
| JP (1) | JP4833962B2 (pt) |
| KR (1) | KR101203403B1 (pt) |
| CN (1) | CN1934131B (pt) |
| AR (1) | AR048191A1 (pt) |
| AT (1) | ATE466022T1 (pt) |
| AU (1) | AU2005230907C1 (pt) |
| BE (1) | BE2015C066I2 (pt) |
| BR (1) | BRPI0509079B8 (pt) |
| CA (1) | CA2560487C (pt) |
| CY (2) | CY1110349T1 (pt) |
| DE (1) | DE602005020913D1 (pt) |
| DK (1) | DK1730175T3 (pt) |
| ES (1) | ES2343255T3 (pt) |
| FR (1) | FR15C0085I2 (pt) |
| HU (1) | HUS1500062I1 (pt) |
| IL (1) | IL178140A (pt) |
| LT (2) | LTPA2015050I1 (pt) |
| LU (1) | LU92903I2 (pt) |
| MY (1) | MY148656A (pt) |
| NL (1) | NL300777I2 (pt) |
| NO (3) | NO338055B1 (pt) |
| NZ (1) | NZ549898A (pt) |
| PL (1) | PL1730175T3 (pt) |
| PT (1) | PT1730175E (pt) |
| RU (1) | RU2373219C2 (pt) |
| SI (1) | SI1730175T1 (pt) |
| TW (1) | TWI349036B (pt) |
| WO (1) | WO2005097821A1 (pt) |
| ZA (1) | ZA200607575B (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| CN1869215B (zh) * | 2006-05-19 | 2012-07-04 | 长春百克生物科技股份公司 | 一种制备人乳头瘤病毒的病毒样颗粒的方法 |
| CN101622008A (zh) | 2007-03-09 | 2010-01-06 | 默克公司 | 乳头瘤病毒疫苗组合物 |
| EP2479187A1 (en) | 2007-11-23 | 2012-07-25 | Shanghai Zerun Biotechnology Co., Ltd. | Genes encoding major capsid protein L1 of human papilloma viruses |
| CN101440371B (zh) * | 2007-11-23 | 2012-09-05 | 上海泽润生物科技有限公司 | 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因 |
| MX340739B (es) * | 2010-05-14 | 2016-07-22 | Brookhaven Science Ass Llc | Quimeras ospa y su uso en vacunas. |
| CA2799205A1 (en) | 2010-05-25 | 2011-12-01 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
| US9499591B2 (en) | 2010-07-02 | 2016-11-22 | Xiamen University | Truncated L1 protein of human papillomavirus type 52 |
| US8361720B2 (en) * | 2010-11-15 | 2013-01-29 | Exact Sciences Corporation | Real time cleavage assay |
| CN103562392B (zh) | 2010-12-03 | 2016-07-20 | Ms技术有限责任公司 | 植物细胞中草甘膦抗性编码核酸分子的优化表达 |
| CN102154325B (zh) * | 2011-01-01 | 2013-08-21 | 上海生物制品研究所有限责任公司 | 针对人乳头瘤状病毒的疫苗及其制法和用途 |
| RU2445357C1 (ru) * | 2011-02-15 | 2012-03-20 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16 |
| RU2445358C1 (ru) * | 2011-02-15 | 2012-03-20 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18 |
| CN104120089B (zh) * | 2013-04-26 | 2019-09-24 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv52 l1蛋白的方法 |
| CN110592133A (zh) * | 2013-05-17 | 2019-12-20 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv31 l1蛋白的方法 |
| EP3057612B1 (en) | 2013-10-16 | 2020-05-06 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
| CN104878022A (zh) * | 2015-04-27 | 2015-09-02 | 段青姣 | 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用 |
| CN106701796B (zh) * | 2015-08-12 | 2021-11-16 | 北京康乐卫士生物技术股份有限公司 | 52型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
| CN109750049B (zh) * | 2017-11-07 | 2023-08-18 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒52亚型蛋白表达 |
| BR112022015313A2 (pt) | 2020-02-14 | 2022-09-27 | Merck Sharp & Dohme Llc | Vacina de hpv |
| CN114539365B (zh) * | 2020-11-26 | 2023-12-01 | 中国医学科学院基础医学研究所 | 一种改造的人乳头瘤病毒52型l1蛋白及其用途 |
| CN113073105B (zh) * | 2021-03-23 | 2023-06-13 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
| CN113549634B (zh) * | 2021-06-07 | 2023-03-31 | 郑州大学 | 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用 |
| AR126708A1 (es) | 2021-08-06 | 2023-11-08 | Merck Sharp & Dohme Llc | Vacuna para el vph |
| CA3229064A1 (en) | 2021-08-19 | 2023-02-23 | Andrew Bett | Thermostable lipid nanoparticle and methods of use thereof |
| TW202513091A (zh) | 2023-06-09 | 2025-04-01 | 美商默沙東有限責任公司 | 用於人類乳突病毒疫苗之奈米乳液佐劑組合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1339729C (en) * | 1988-10-26 | 1998-03-17 | Wayne D. Lancaster | Human papillomavirus type 52 dna sequences and methods for employing thesame |
| IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
| CA2280195A1 (en) | 1997-02-07 | 1998-08-13 | Merck & Co., Inc. | Synthetic hiv gag genes |
| EP1002091B1 (en) | 1997-07-09 | 2012-02-29 | Coridon Pty Limited | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| CA2339324C (en) | 1998-08-14 | 2011-05-31 | Robert S. Lowe | Protein delivery system using human papillomavirus virus-like particles |
| PL347472A1 (en) * | 1998-08-14 | 2002-04-08 | Merck & Co Inc | Process for purifying human papillomavirus virus-like particles |
| SE514982C2 (sv) * | 1999-09-30 | 2001-05-28 | Active Biotech Ab | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
| ATE284898T1 (de) * | 1999-08-25 | 2005-01-15 | Merck & Co Inc | Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind |
| US6436402B1 (en) | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
| ATE346947T1 (de) | 2000-07-21 | 2006-12-15 | Glaxo Group Ltd | Kodon-optimierte papillomavirussequenzen |
| US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| ES2381964T3 (es) | 2003-03-24 | 2012-06-04 | Merck Sharp & Dohme Corp. | Expresión optimizada de L1 de VPH 31 en levadura |
| MY140664A (en) * | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
| MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
-
2005
- 2005-03-18 BR BRPI0509079A patent/BRPI0509079B8/pt not_active IP Right Cessation
- 2005-03-18 DK DK05725933.5T patent/DK1730175T3/da active
- 2005-03-18 AT AT05725933T patent/ATE466022T1/de active
- 2005-03-18 CN CN2005800095956A patent/CN1934131B/zh not_active Expired - Lifetime
- 2005-03-18 NZ NZ549898A patent/NZ549898A/en not_active IP Right Cessation
- 2005-03-18 JP JP2007505032A patent/JP4833962B2/ja not_active Expired - Lifetime
- 2005-03-18 AU AU2005230907A patent/AU2005230907C1/en active Active
- 2005-03-18 DE DE602005020913T patent/DE602005020913D1/de not_active Expired - Lifetime
- 2005-03-18 ES ES05725933T patent/ES2343255T3/es not_active Expired - Lifetime
- 2005-03-18 PL PL05725933T patent/PL1730175T3/pl unknown
- 2005-03-18 TW TW094108431A patent/TWI349036B/zh active
- 2005-03-18 MY MYPI20051180A patent/MY148656A/en unknown
- 2005-03-18 RU RU2006137363/13A patent/RU2373219C2/ru active
- 2005-03-18 EP EP05725933A patent/EP1730175B1/en not_active Expired - Lifetime
- 2005-03-18 US US10/594,064 patent/US7700103B2/en active Active
- 2005-03-18 PT PT05725933T patent/PT1730175E/pt unknown
- 2005-03-18 CA CA2560487A patent/CA2560487C/en not_active Expired - Lifetime
- 2005-03-18 WO PCT/US2005/009199 patent/WO2005097821A1/en not_active Ceased
- 2005-03-18 KR KR1020067019673A patent/KR101203403B1/ko not_active Expired - Lifetime
- 2005-03-18 SI SI200531052T patent/SI1730175T1/sl unknown
- 2005-03-23 AR ARP050101174A patent/AR048191A1/es active IP Right Grant
-
2006
- 2006-09-11 ZA ZA200607575A patent/ZA200607575B/xx unknown
- 2006-09-17 IL IL178140A patent/IL178140A/en active IP Right Grant
- 2006-10-23 NO NO20064815A patent/NO338055B1/no active Protection Beyond IP Right Term
-
2009
- 2009-10-14 US US12/578,995 patent/US7744892B2/en not_active Expired - Lifetime
-
2010
- 2010-07-26 CY CY20101100698T patent/CY1110349T1/el unknown
-
2015
- 2015-11-30 NL NL300777C patent/NL300777I2/nl unknown
- 2015-12-02 HU HUS1500062C patent/HUS1500062I1/hu unknown
- 2015-12-04 FR FR15C0085C patent/FR15C0085I2/fr active Active
- 2015-12-07 CY CY2015052C patent/CY2015052I1/el unknown
- 2015-12-08 LT LTPA2015050D patent/LTPA2015050I1/lt unknown
- 2015-12-08 LU LU92903C patent/LU92903I2/xx unknown
- 2015-12-08 LT LTPA2015050C patent/LTC1730175I2/lt unknown
- 2015-12-09 BE BE2015C066C patent/BE2015C066I2/nl unknown
-
2017
- 2017-01-20 NO NO2017005C patent/NO2017005I1/no unknown
-
2022
- 2022-11-30 NO NO2022050C patent/NO2022050I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0509079B8 (pt) | molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal | |
| BRPI0408639A (pt) | molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, método para produzir partìculas semelhantes a vìrus, vacina, composições farmacêuticas, e, métodos para prevenir a infecção por hpv e para induzir uma resposta imune em um animal | |
| BRPI0416393A (pt) | molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, métodos para produzir as mesmas, para prevenir infecção por hpv, e para induzir uma resposta imune em um animal, vacina, composições farmacêuticas, e, polipeptìdeo hpv58 l1 isolado e purificado | |
| BRPI0414845A (pt) | mólecula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, método para produzir as partìculas semelhantes a vìrus, vacina, composições farmacêuticas, e, métodos para prevenir infecção por hpv e para induzir uma resposta imune em um animal | |
| van Riet et al. | Mucosal IgA responses in influenza virus infections; thoughts for vaccine design | |
| CN102675471B (zh) | 猪口蹄疫病毒o型广谱多表位重组抗原及其应用 | |
| JP2021534182A (ja) | 免疫原性組成物及びその使用 | |
| Zheng et al. | Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses | |
| BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
| Su et al. | The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650 | |
| WO2021231925A8 (en) | Vaccines for recurrent respiratory papillomatosis and methods of using the same | |
| CA3234653A1 (en) | Influenza vaccines | |
| WO2009074861A3 (en) | Improved vaccine | |
| MX2022016287A (es) | Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas. | |
| CN102657864B (zh) | 一种口蹄疫疫苗的免疫佐剂及其应用 | |
| CN101864434B (zh) | 羊口蹄疫病毒Asia1型多表位重组疫苗及制备方法 | |
| EP1427443A4 (en) | VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR | |
| Nuñez-Ortiz et al. | Immunostimulant properties of full-length and truncated Marinobacter algicola flagellins, and their effects against viral hemorrhagic septicemia virus (VHSV) in trout | |
| WO2005123121A3 (en) | Use of dna molecule as vaccine adjuvant | |
| TW200607858A (en) | Optimized expression of HPV 31 L1 in yeast | |
| Tavakoli et al. | Cloning and Expression of Recombinant Nucleoprotein of Influenza H1N1 | |
| TH82139B (th) | การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์ | |
| Wee et al. | Swine Influenza Virus Recombinant HA Protein Expressed in the Baculovirus System Elicited Protective Immunity in Mice | |
| RU2010121411A (ru) | Рекомбинантная вакцина против вируса "свиного" гриппа h1n1 и способ ее получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) Free format text: ALTERADO DE: MERCK AND CO., INC. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: SCHERING CORPORATION, (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2576 DE 19/05/2020 QUANTO A QUALIFICACAO DO TITULAR E O TITULO. |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 18/03/2025 |